Cargando…
Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer
AIM: To provide an overview on the available treatments to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published and assessed the validity o...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305090/ https://www.ncbi.nlm.nih.gov/pubmed/32166452 http://dx.doi.org/10.1007/s00066-020-01598-9 |
_version_ | 1783548385264926720 |
---|---|
author | Ghadjar, Pirus Aebersold, Daniel M. Albrecht, Clemens Böhmer, Dirk Flentje, Michael Ganswindt, Ute Höcht, Stefan Hölscher, Tobias Müller, Arndt-Christian Niehoff, Peter Pinkawa, Michael Sedlmayer, Felix Zips, Daniel Wiegel, Thomas |
author_facet | Ghadjar, Pirus Aebersold, Daniel M. Albrecht, Clemens Böhmer, Dirk Flentje, Michael Ganswindt, Ute Höcht, Stefan Hölscher, Tobias Müller, Arndt-Christian Niehoff, Peter Pinkawa, Michael Sedlmayer, Felix Zips, Daniel Wiegel, Thomas |
author_sort | Ghadjar, Pirus |
collection | PubMed |
description | AIM: To provide an overview on the available treatments to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published and assessed the validity of the information on efficacy and treatment-related toxicity. RESULTS: Eight randomized controlled trials and one meta-analysis were identified. Two randomized trials demonstrated that prophylactic radiation therapy (RT) using 1 × 10 Gy or 2 × 6 Gy significantly reduced the rate of gynecomastia but not breast pain, as compared to observation. A randomized dose-finding trial identified the daily dose of 20 mg tamoxifen (TMX) as the most effective prophylactic dose and another randomized trial described that daily TMX use was superior to weekly use. Another randomized trial showed that prophylactic daily TMX is more effective than TMX given at the onset of gynecomastia. Two other randomized trials described that TMX was clearly superior to anastrozole in reducing the risk for gynecomastia and/or breast pain. One comparative randomized trial between prophylactic RT using 1 × 12 Gy and TMX concluded that prophylactic TMX is more effective compared to prophylactic RT and furthermore that TMX appears to be more effective to treat gynecomastia and/or breast pain when symptoms are already present. A meta-analysis confirmed that both prophylactic RT and TMX can reduce the risk of gynecomastia and/or breast pain with TMX being more effective; however, the rate of side effects after TMX including dizziness and hot flushes might be higher than after RT and must be taken into account. Less is known regarding the comparative effectiveness of different radiation fractionation schedules and more modern RT techniques. CONCLUSIONS: Prophylactic RT as well as daily TMX can significantly reduce the incidence of gynecomastia and/or breast pain. TMX appears to be an effective alternative to RT also as a therapeutic treatment in the presence of gynecomastia but its side effects and off-label use must be considered. |
format | Online Article Text |
id | pubmed-7305090 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-73050902020-06-22 Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer Ghadjar, Pirus Aebersold, Daniel M. Albrecht, Clemens Böhmer, Dirk Flentje, Michael Ganswindt, Ute Höcht, Stefan Hölscher, Tobias Müller, Arndt-Christian Niehoff, Peter Pinkawa, Michael Sedlmayer, Felix Zips, Daniel Wiegel, Thomas Strahlenther Onkol Review Article AIM: To provide an overview on the available treatments to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer. METHODS: The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published and assessed the validity of the information on efficacy and treatment-related toxicity. RESULTS: Eight randomized controlled trials and one meta-analysis were identified. Two randomized trials demonstrated that prophylactic radiation therapy (RT) using 1 × 10 Gy or 2 × 6 Gy significantly reduced the rate of gynecomastia but not breast pain, as compared to observation. A randomized dose-finding trial identified the daily dose of 20 mg tamoxifen (TMX) as the most effective prophylactic dose and another randomized trial described that daily TMX use was superior to weekly use. Another randomized trial showed that prophylactic daily TMX is more effective than TMX given at the onset of gynecomastia. Two other randomized trials described that TMX was clearly superior to anastrozole in reducing the risk for gynecomastia and/or breast pain. One comparative randomized trial between prophylactic RT using 1 × 12 Gy and TMX concluded that prophylactic TMX is more effective compared to prophylactic RT and furthermore that TMX appears to be more effective to treat gynecomastia and/or breast pain when symptoms are already present. A meta-analysis confirmed that both prophylactic RT and TMX can reduce the risk of gynecomastia and/or breast pain with TMX being more effective; however, the rate of side effects after TMX including dizziness and hot flushes might be higher than after RT and must be taken into account. Less is known regarding the comparative effectiveness of different radiation fractionation schedules and more modern RT techniques. CONCLUSIONS: Prophylactic RT as well as daily TMX can significantly reduce the incidence of gynecomastia and/or breast pain. TMX appears to be an effective alternative to RT also as a therapeutic treatment in the presence of gynecomastia but its side effects and off-label use must be considered. Springer Berlin Heidelberg 2020-03-12 2020 /pmc/articles/PMC7305090/ /pubmed/32166452 http://dx.doi.org/10.1007/s00066-020-01598-9 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Article Ghadjar, Pirus Aebersold, Daniel M. Albrecht, Clemens Böhmer, Dirk Flentje, Michael Ganswindt, Ute Höcht, Stefan Hölscher, Tobias Müller, Arndt-Christian Niehoff, Peter Pinkawa, Michael Sedlmayer, Felix Zips, Daniel Wiegel, Thomas Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer |
title | Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer |
title_full | Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer |
title_fullStr | Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer |
title_full_unstemmed | Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer |
title_short | Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer |
title_sort | treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: statement from the degro working group prostate cancer |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7305090/ https://www.ncbi.nlm.nih.gov/pubmed/32166452 http://dx.doi.org/10.1007/s00066-020-01598-9 |
work_keys_str_mv | AT ghadjarpirus treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT aebersolddanielm treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT albrechtclemens treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT bohmerdirk treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT flentjemichael treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT ganswindtute treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT hochtstefan treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT holschertobias treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT mullerarndtchristian treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT niehoffpeter treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT pinkawamichael treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT sedlmayerfelix treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT zipsdaniel treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT wiegelthomas treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer AT treatmentstrategiestopreventandreducegynecomastiaandorbreastpaincausedbyantiandrogentherapyforprostatecancerstatementfromthedegroworkinggroupprostatecancer |